Kazia Therapeutics' lead asset, Paxalisib, showed stronger concurrent-control survival data in GBM, but FDA accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results